By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.
Sanofi’s Toujeo® (Insulin glargine 300 units/mL) has been approved for use in Scotland, the pharmaceutical company has announced. The Scottish Medicines Consortium (SMC) has approved the ...
Sanofi has announced today that Toujeo® (insulin glargine [rDNA origin] 300 units/mL), a long-acting, once-daily basal insulin treatment is available for clinicians to prescribe in the UK. The ...
Sanofi’s combination type 2 diabetes drug LixiLan has met its primary endpoint in its first Phase III trial. The pharmaceutical firm announced today that the LixiLan-O Phase III clinical trial ...
Sanofi has today announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with Type 2 diabetes ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has announced a positive opinion recommending variation to the marketing authorisation of Toujeo (insulin ...
An inhaled insulin has gone on sale in America this month. Afrezza, developed by MannKind and licensed to pharmaceutical company Sanofi, is available in the US market for people with Type 1 or ...
A new app to encourage children to learn more about how to live with diabetes has been launched. Mission T1D by Sanofi Diabetes is aimed at children with Type 1 diabetes and their parents and ...
A new healthcare app aimed at helping children with Type 1 diabetes better manage their condition has been shortlisted in the Health Service Journal (HSJ) Value in Healthcare Awards. Monster ...
Sanofi has launched the first self-monitoring device that provides estimates of the HbA1c value, a key indicator for long-term glucose control. The company claims its MyStar Extra® blood glucose ...
A programme to recognise, reward and share good practise in diabetes management, education and patient care has been launched at the UK’s leading diabetes conference. The fourth Quality in ...